Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed next steps in the evaluation of tildrakizumab for the treatment of psoriasis.
Next investigative targets for the evaluation of tildrakizumab in the treatment of psoriasis will address its efficacy on more sensitive affected areas, such as the scalp, nails, face, and neck, said Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America.
Rozzo served as co-author of 2 studies presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting: "Real-world Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Plaque Psoriasis: Week 28 Interim Analysis of a Phase 4 Study” and “A Phase 4, Real-world Study of Tildrakizumab in Moderate-to-Severe Psoriasis: Week 28 Interim Analysis.”
What further investigation is being considered for tildrakizumab in the treatment of psoriasis?
The next steps are to look at various topics that are not only traditionally examined in such patients—for example, scalp psoriasis we have an investigation underway for that, and nails with psoriasis often have effects—but we're also looking at some issues that are frequently of concern to patients and providers that are often not looked at that carefully.
For example, many companies will look at lesions on the head, on the scalp, but they don't necessarily do careful examination of lesions on the face or the neck, which are obviously very important to patients. Nobody wants to have any kind of lesion like that. So, we're taking a careful look at that. And we especially want to look at the patients with the 50% worst disease.
We set the bar very high. We want to see complete clearance, complete elimination of disease activity. So, we try to think of the problems patients face with psoriasis from their view and also from the health care providers' view, because they obviously want their patients to be all better as well.